Humasis Co

Humasis Co Accounts Payable

The Accounts Payable of Humasis Co (205470.KQ) as of Oct 27, 2026 is 267.51 M KRW. In the previous year, Accounts Payable was 234.70 M KRW — a change of 13.98% (higher).

Accounts Payable

267.51 MKRW

YoY

13.98%

Last updated:

Accounts Payable of Humasis Co is 2025 267.51 M KRW. Accounts Payable of Humasis Co was 2024 234.70 M KRW. It decreases by 13.98% higher compared to the previous year.

The Humasis Co Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
655.68 M KRW
Jan 1, 2020
2.46 B KRW
Jan 1, 2021
34.25 B KRW
Jan 1, 2022
6.22 B KRW
Jan 1, 2023
456.33 M KRW
Jan 1, 2024
234.70 M KRW
Jan 1, 2025
267.51 M KRW
The Humasis Co Accounts Payable history
YEARAccounts PayableYoY
267.51 MKRW+13.98%
234.70 MKRW-48.57%
456.33 MKRW-92.66%
6.22 BKRW-81.85%
34.25 BKRW+1,290.68%
2.46 BKRW+275.65%
655.68 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Accounts Payable of Humasis Co is 267.51 M KRW in 2025.

Accounts Payable of Humasis Co changed from 234.70 M KRW to 267.51 M KRW, representing a 13.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co